Medication Exposure in Pregnancy Risk Evaluation Program(MEPREP)

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Knowledge about safe medication use during pregnancy is limited, yet about two of every three women take at least one prescription medication during pregnancy, furthermore, there is a lack of rigorous studies evaluating birth outcomes associated with in utero exposure to medications. The Medication Exposure in Pregnancy Risk Evaluation Program (MEPREP) is intended to provide a mechanism for collaborative pharmacoepidemiological research to address the safety of pharmaceutical product exposure during pregnancy, through the development of standardized data requirements and of the necessary data linkages of mother-infant pairs to conduct multi-site investigations. This presentation will describe the program, the types of data collected, and progress to date. The current MEPREP population includes female health plan members of 11 distinct health management entities within three research centres who have delivered an infant between January 1, 2001 and December 31, 2007, along with the administrative and birth certificate data on over one million children linked to mothers. There is information on all the medications those mothers took, as well as most of the outcomes of the babies. One of the benefits of this dataset is the information that could be investigated, such as birth weight, fetal growth, congenital anomalies, perinatal conditions, etc., against various demographics of the women in the dataset. The population size within the dataset suggests that various parameters could be studied with at least a modest degree of power.

Original languageEnglish (US)
JournalCanadian Journal of Clinical Pharmacology
Volume17
Issue number3
StatePublished - 2010
Externally publishedYes

Fingerprint

Program Evaluation
Pregnancy
Mothers
Birth Certificates
Population Control
Information Storage and Retrieval
Health
Fetal Development
Population Density
Research
Birth Weight
Prescriptions
Demography
Parturition
Safety
Pharmaceutical Preparations
Datasets

All Science Journal Classification (ASJC) codes

  • Pharmacology (medical)
  • Health Policy

Cite this

Medication Exposure in Pregnancy Risk Evaluation Program(MEPREP). / Davis, Robert.

In: Canadian Journal of Clinical Pharmacology, Vol. 17, No. 3, 2010.

Research output: Contribution to journalArticle

@article{a1f9e5d932954622aca003afb3077259,
title = "Medication Exposure in Pregnancy Risk Evaluation Program(MEPREP)",
abstract = "Knowledge about safe medication use during pregnancy is limited, yet about two of every three women take at least one prescription medication during pregnancy, furthermore, there is a lack of rigorous studies evaluating birth outcomes associated with in utero exposure to medications. The Medication Exposure in Pregnancy Risk Evaluation Program (MEPREP) is intended to provide a mechanism for collaborative pharmacoepidemiological research to address the safety of pharmaceutical product exposure during pregnancy, through the development of standardized data requirements and of the necessary data linkages of mother-infant pairs to conduct multi-site investigations. This presentation will describe the program, the types of data collected, and progress to date. The current MEPREP population includes female health plan members of 11 distinct health management entities within three research centres who have delivered an infant between January 1, 2001 and December 31, 2007, along with the administrative and birth certificate data on over one million children linked to mothers. There is information on all the medications those mothers took, as well as most of the outcomes of the babies. One of the benefits of this dataset is the information that could be investigated, such as birth weight, fetal growth, congenital anomalies, perinatal conditions, etc., against various demographics of the women in the dataset. The population size within the dataset suggests that various parameters could be studied with at least a modest degree of power.",
author = "Robert Davis",
year = "2010",
language = "English (US)",
volume = "17",
journal = "Journal of Population Therapeutics and Clinical Pharmacology",
issn = "1198-581X",
publisher = "Pulsus Group Inc.",
number = "3",

}

TY - JOUR

T1 - Medication Exposure in Pregnancy Risk Evaluation Program(MEPREP)

AU - Davis, Robert

PY - 2010

Y1 - 2010

N2 - Knowledge about safe medication use during pregnancy is limited, yet about two of every three women take at least one prescription medication during pregnancy, furthermore, there is a lack of rigorous studies evaluating birth outcomes associated with in utero exposure to medications. The Medication Exposure in Pregnancy Risk Evaluation Program (MEPREP) is intended to provide a mechanism for collaborative pharmacoepidemiological research to address the safety of pharmaceutical product exposure during pregnancy, through the development of standardized data requirements and of the necessary data linkages of mother-infant pairs to conduct multi-site investigations. This presentation will describe the program, the types of data collected, and progress to date. The current MEPREP population includes female health plan members of 11 distinct health management entities within three research centres who have delivered an infant between January 1, 2001 and December 31, 2007, along with the administrative and birth certificate data on over one million children linked to mothers. There is information on all the medications those mothers took, as well as most of the outcomes of the babies. One of the benefits of this dataset is the information that could be investigated, such as birth weight, fetal growth, congenital anomalies, perinatal conditions, etc., against various demographics of the women in the dataset. The population size within the dataset suggests that various parameters could be studied with at least a modest degree of power.

AB - Knowledge about safe medication use during pregnancy is limited, yet about two of every three women take at least one prescription medication during pregnancy, furthermore, there is a lack of rigorous studies evaluating birth outcomes associated with in utero exposure to medications. The Medication Exposure in Pregnancy Risk Evaluation Program (MEPREP) is intended to provide a mechanism for collaborative pharmacoepidemiological research to address the safety of pharmaceutical product exposure during pregnancy, through the development of standardized data requirements and of the necessary data linkages of mother-infant pairs to conduct multi-site investigations. This presentation will describe the program, the types of data collected, and progress to date. The current MEPREP population includes female health plan members of 11 distinct health management entities within three research centres who have delivered an infant between January 1, 2001 and December 31, 2007, along with the administrative and birth certificate data on over one million children linked to mothers. There is information on all the medications those mothers took, as well as most of the outcomes of the babies. One of the benefits of this dataset is the information that could be investigated, such as birth weight, fetal growth, congenital anomalies, perinatal conditions, etc., against various demographics of the women in the dataset. The population size within the dataset suggests that various parameters could be studied with at least a modest degree of power.

UR - http://www.scopus.com/inward/record.url?scp=84873424126&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84873424126&partnerID=8YFLogxK

M3 - Article

VL - 17

JO - Journal of Population Therapeutics and Clinical Pharmacology

JF - Journal of Population Therapeutics and Clinical Pharmacology

SN - 1198-581X

IS - 3

ER -